NCT00326885 2018-10-17Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesNeovii BiotechPhase 2 Completed32 enrolled 12 charts
NCT01320020 2013-07-02A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer PatientsNeovii BiotechPhase 1 Terminated16 enrolled
NCT00377429 2012-07-19Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to ChemotherapyNeovii BiotechPhase 2 Completed47 enrolled 11 charts